Alzheimer's disease (AD) treatment represents one of the largest unmet medical needs.
Introduction
Alzheimer's disease (AD) is the most common form of senile dementia affecting millions of people worldwide. Characterized by the gradual loss of cognitive functions due to abnormal deposition of extracellular fibrillar amyloid beta peptides (Aβ) and intracellular neurofibrillary tangles in the brain, AD poses tremendous social and economic burdens for families and societies 1, 2 . It has been hypothesized that targeting Aβ neurotoxicity is a potentially effective method to treat AD. Unfortunately, after decades of intensive pursuit, there is still no immediate hope of translating such knowledge into a pharmaceutical therapy for AD 3, 4 . For example, cholinesterase inhibitors were the first generation of such candidate therapeutics [5] [6] [7] .
A second generation of candidate therapeutics includes attempts to inhibit the formation of amyloid plaques. Active and passive immunization approaches are presently being developed 8 , despite of the adverse immune reactions in the active human immunization trials in some patients 9, 10 . Another alternative has been to reduce the levels of Aβ in the brain by inhibiting the proteolytic enzymes associated with trimming APP into Aβ 40 or 42 9 .
The Aβ1-42 fibril is the predominant constituent of amyloid plaques despite Aβ1-40 being more abundant in the plasma 11 . The observation that Aβ1-42 oligomers form calcium conducting channels in the neuronal bilayer membranes 12, 13 led to the search for calcium channel inhibitors. The nonspecific Aβ channel blockers, such as tromethamine (Tris) and Zn 2+ , have been reported to inhibit Aβ neurotoxicity 14, 15 . Glutamate receptors, including NMDA type and AMPA type receptors, are also involved in Aβ neurotoxicity through increased Ca 2+ influx 13 . Thus, calcium homeostasis plays critical roles in the mechanisms of Aβ-induced neurotoxicity 16, 17 anti-oxidation, scavenging free radicals, anti-inflammation, antimicrobial and anti-cancer activities [22] [23] [24] . Importantly, the anti-oxidation and anti-inflammation properties of GA contribute to neuroprotection against Alzheimer's disease 22, 25 . Together these studies led us to hypothesize that GA is a potential candidate for AD drug development.
In the present study, APPswe/PS1dE9 double transgenic mouse AD model (APP/PS1) was used to investigate the therapeutic effects of GA in both early and late stages of disease development. The APP/PS1 mouse was generated by co-injecting two vectors encoding the human mutant APP and PSEN1 to produce elevated Aβ levels 26 . At the age of 4-month-old, these mice begin to develop small amount of Aβ plaque deposition and show working memory deficits 27 . At the age of 9-month-old, these mice develop pronounced cognitive deficits. A battery of behavioral tests was performed to show that GA was effective in rescuing cognitive deficits during both the early and late stages of AD development. The possible mechanisms were through disrupting Aβ1-42 fibril formation. Collectively, these studies demonstrated that GA is a good lead for the development as a therapeutic drug against AD.
Materials and Methods

Preparation of Aβ1-42
Synthetic human Aβ1-42 (>95%) was purchased from GL Biochem (Shanghai, China) and prepared as preciously described 28 . Briefly, fresh Aβ1-42 powder was dissolved in 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP, Fluka, USA) to achieve a final concentration of 1 mM. The solution was left in quiescence for 1 h at room temperature, which was then distributed into aliquots in new centrifuge tubes with opened lids for evaporation at room temperature for about 3 h. Afterwards, it was followed by drying in a speed-vac concentrator (CentriVap® Concentrator, Labconco, USA) at 37°C for 1h. The lyophilized peptides were stored at -20°C until use. To obtain oligomeric Aβ1-42, the HFIP-treated peptides was re-dissolved in DMSO to a concentration of 2.5 mM and sonicated in a water bath for 5 min.
The solution was then diluted in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 to 100 μM and incubated for 48 h at 4 °C. After that, the solution was centrifuged at 12000 rpm for 10 min at 4 °C, and the supernatant was collected for the subsequent experiment.
To produce aggregated Aβ1-42 20 , the HFIP-treated Aβ1-42 peptides was re-dissolved in 10 mM NaOH to a concentration of 2.5 mM and sonicated in a cold water bath for 30 min, followed by dilution in PBS to the required concentration. The solution was incubated for 3 days at 37 °C to form aggregated Aβ1-42.
Neuronal viability assay using CCK8 kit
Neuronal viability was assessed with a cell viability counting kit -8 purchased from BBI Life Sciences (Shanghai, China). Briefly, primary cortical neurons treated with Aβ1-42 for the specified period of time and the amount were collected following the manufacturer's protocol.
Exactly 100 μL of cell suspension was transferred to a 96-well plate at a final concentration of 500,000 cells/mL. Cells were incubated with 10 µL CCK-8 solution from the kit per well for 4 h and assessed with a Perkin-Elmer spectrometer (EnSpire, Perkin-Elmer, USA) at the absorbance of 450 nm.
Quantification of Aβ plaques using Thioflavin S staining
Thioflavin S staining of frozen brain sections was performed as previously described with 
Thioflavin T (ThT) fluorescence assay
Thioflavin T (ThT) fluorescence is used regularly to quantify the formation and inhibition of amyloid fibrils in the presence of anti-amyloidogenic compounds such as polyphenols.
Thioflavin T (ThT) assay was performed as previously described with minor modifications
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.
Briefly, Aβ1-42 powder was dissolved in 1mL 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP), sonicated for 5 min to completely dissolve the Aβ1-42, followed by incubation for 1 h at room temperature, and aliquoted into 1.5 mL microcentrifuge tubes. HFIP in each tube was completely evaporated over 3 h in a fume hood, followed by evaporation for 1 h in a SpeedVac concentrator (CentriVap® Concentrator, Labconco, USA) at the room temperature.
To produce aggregated Aβ1-42, the HFIP-treated Aβ1-42 peptides was re-dissolved in 10 mM NaOH and sonicated in cold water bath for 30 min, diluted to a final concentration of 25 μM in PBS (pH 7.4). The Aβ1-42 solution was incubated for 3 d at 37 °C to form aggregated Aβ1-42.
Aβ1-42 fibrils at 20 μM concentration were mixed with different concentrations of GA. The mixture was added into a 96-well plate at 200 μL/well, followed by incubating with 10 μM ThT for 15 min at 37 °C before recording. Fluorescence from ThT was detected using a Perkin-Elmer Luminescence spectrometer (EnSpire™ Multilabel Reader, Perkin-Elmer, Singapore). Excitation and emission wavelengths for fluorescence spectroscopy were at 450 nm and 485 nm, respectively.
Dynamic light scattering (DLS) assay
DLS measurements were performed using a Zetasizer Nano S (Malvern Instruments, Worcestershire, UK) according to the method described in 22 . For in situ measurements, 8 autocorrelation functions of scattered light were collected using acquisition times of 3 min and converted into particle-size distributions using the "narrow modes" or "general purpose"
algorithms provided with the Zetasizer Nano S. Changes in scattering intensity were derived from the count rates of the avalanche photodiode photon detector.
DLS measurements
Aggregation state of Aβ1-42 with the presence of GA was further determined using DLS . Mice were maintained in a SPF II animal facility with controlled environment (temperature: 22 ± 1°C; humidity: 50 ± 10 %, and a 12 h light/dark cycle). Mice were allowed food and water ad libitum. These mice were bred with C57BL/6 mice to establish a colony of APP/PS1 mice and wildtype littermates. Genotyping of mice was carried out using tail tip DNA following the standard DNA extraction and PCR protocol.
Gallic acid administration
We used APP/PS1 and their wildtype littermates to examine whether GA could ameliorate AD pathology and cognitive deficits in vivo. GA treatment was given to both the 4 month-old group and the 9-month-old groups. GA was dissolved in sterile water at the concentration of 3 mg/mL, and was given to mice daily at 30 mg/kg through gavage as previously described 25 .
Sterile water was given to mice serving as a vehicle-treated control group. All mice were weighted every week in the morning. After GA treatment, mice were subjected to a suit of behavioral tests.
Mouse behavioral tests
Open field test:
After the last GA administration, mice spontaneous activity in the open field were tested using a clear plastic cube box (41× 41× 38 cm) under a camera, the center region was defined as a 20 cm × 20 cm virtual area. Each mouse was given 10 min to move freely in the box. All traveled distances and the distance trace center was recorded and analyzed using Smart V3.0, Panlab software. The rearing number, representing the number of times mouse lifting the forepaws to explore upwards, was recorded by the experimenter.
Morris water maze (MWM):
Morris water maze was performed to determine the spatial learning ability and reference memory. MWM was performed in a blue water pool (120 cm in diameter with 2/3 of transparent water) containing a circular bright blue platform (14 cm in diameter and submerged 1.5 cm beneath the water surface).
Spatial acquisition test:
The spatial acquisition learning ability training consisted of five consecutive days of training with every training day comprising of four trials with 15 min inter-trial interval. The entry points randomly selected each time from the different designated locations. Once mouse successfully found the platform within 60 s, it was placed into a cage under a warming lamp. Otherwise, mouse was gently and manually guided to the platform and allowed to remain there for at least 20 s. The traveled distance to platform was recorded in each day to assess the spatial learning ability.
Probe trial test: On day 6, a probe trial test was performed. The hidden platform was removed from the pool and the mouse was placed in the quadrant diagonally opposite the target quadrant and allowed to swim for 60 s. The time spent in the target quadrant and mean distance to target were recorded and analyzed as a measure of spatial memory retention (or the reference memory) 33 . Mice were monitored by a camera and its trajectory was analyzed using the Smart V3.0, Panlab software.
Y-maze spontaneous alternations:
To assess spatial working memory of the mice, 
Novel object recognition test:
The novel object recognition test was carried out to assess the short-term recognition memory after the Y maze test. The task was adapted to the experimental setting as described previously 35 . Each trial of a mouse consisted of a familiarization session and a test session. In the familiarization session, each mouse was individually placed into an open field testing box, mouse was allowed to explore freely for 10 min in the box with two identical objects on the symmetrical diagonal position. One hour after the familiarization, one familiarized object in the box was replaced with a novel object having different brightness, shape and texture. In the test session, mouse was put back into the box again and given 5 min to explore the two different objects. The activity of the mice was recorded using Noldus video tracking system (Ethovision). Duration of time was recorded to represent basic tendency of the mouse to sniff and explore novelty objects when the mouse nose point was around the object (distance between the nose and the object was less than 2.5 cm). Discrimination index was defined as the ratio of exploration duration around the novel object over duration around both the objects in the test session.
In order to minimize the difference made by experimenter handling, throughout all behavioral experiments, mice were handled by the same one experimenter.
Electrophysiological recordings of Long term potentiation (LTP)
The method used to obtain LTP was essentially based on a previously described protocol 29, 36 . The transverse hippocampal slices (400 μm) were prepared using a Vibrotome slicer (VT 1000S; Leica) in ice-cold artificial cerebral spinal fluid (aCSF). The composition of aCSF was (in mM): 120 NaCl, 2.5 KCl, 1.2 NaH2PO4, 2.0 CaCl2, 2.0 MgSO4, 26 NaHCO3, and 10 glucose, saturated with 95% O2 / 5% CO2 (v/v). After incubating for 30 min at 34 C and 2 -8 h at the room temperature (25 ± 1 C), the hippocampal slice was kept submerged in aCSF (3 mL/min; 32-34 °C) with a nylon mesh. The same aCSF that injected into the glass pipettes 
GA Binding Docking Modeling
All GA derivatives were purchased from Sigma Aldrich. GA derivatives binding and interaction with Aβ1-42 were examined using Molecular Operating Environment (MOE) 2014.09 software at the atomic level
Statistical analysis
All data were represented as mean ± SEM. 
Results
GA alleviates cognitive impairments of early stage AD mouse
To determine the possible beneficial effect of GA in the early stage of AD development, 4-month-old APP/PS1 transgenic mice were give GA through gavage for 30 d at 30 mg/kg/d.
The drug dosage and route of delivery were chosen based on a previous report of similar animal studies 25 and our in vitro studies. Mice were randomly assigned into four groups (n = 6 -9 per group): WT group, wildtype mice; WT+GA group, wildtype mice treated with GA;
APP/PS1 group, AD transgenic mice; and APP/PS1+GA group, AD transgenic mice treated with GA (Fig 1) . All groups of mice were monitored for physiological changes during the period of oral administration of GA: (1) Mice were weighted every week to confirm no significant changes in body weight (Supplemental Fig. S1A) . (2) The open field test (OFT) was performed at the end of the last GA oral administration to monitor the spontaneous activity of GA-treated mice. All four groups showed no significant differences (Supplemental Fig. S1B-D) .
Cerebral blood flow of all groups was measured using Moor FLPI-2 (full-field laser perfusion imager) to exclude the possibility that GA may affect cerebral blood flow (Supplemental Fig.   S3 ). These experiments indicated that GA treatment did not have a major negative impact on mouse normal brain physiology.
Subsequently, a battery of behavioral tests was carried out on these mice as depicted in transgenic mice group exhibited mild deficit in memory retention as shown by the appearance of more random location searches, a longer mean distance of path length to target (p < 0.01, Fig 1C) , and a lesser amount of time spent in the target quadrant (p< 0.01, Fig 1D) compared to the WT littermate mice (Fig 1C, D) . By contrast, GA-treated group of APP/PS1 mice (APP/PS1+GA group) spent significantly more amount of time in the target quadrant (p < 0.05, Fig 1D) compared with those of APP/PS1 group. These data demonstrated that GA improved the spatial reference memory deficit in the young AD mice.
In addition, NORT was performed which showed no significant differences amongst all groups in the discrimination index, indicating clear preferences for the exploration of novel objects during the test session (Fig 1E) . In contrast, Y-maze test, which evaluates spatial working memory, showed that the APP/PS1 group exhibited a significantly lower alternation behavior than the WT group (p < 0.001, Fig 1F) , confirming deficits in remembering which arm was explored. This alternation behavior deficit was significantly ameliorated in the APP/PS1+GA group (p < 0.05, Fig. 1F ), demonstrating that GA was effective in enhancing spatial working memory during the early stage of AD development.
GA alleviates cognitive impairments of late stage AD mouse
To determine whether GA can also reduce the more severe cognitive deficits of AD mice at a relatively late stage, the 9-month-old APP/PS1 transgenic mouse was given GA orally The 9-month-old APP/PS1 mice exhibited significant cognitive impairments before GA treatment (Fig 2B-F) . The spatial learning ability of APP/PS1 mice was significantly impaired based on the spatial acquisition trials of the MWM test (Fig 2B, The discrimination index of the APP/PS1 mice in the NORT test showed significant reduction compared with that of the WT mice (Fig 2E, p < littermates with APP/PS1 mice showed no statistically significant difference (Fig 3A) .
However, LTP generated in the 10-month-old APP/PS1 group of mice was significantly reduced compared to the WT littermate group of mice (Fig 3B and C; 
Gallic acid treatment reduces the Aβ plaque size in the APP/PS1 mice brain
To determine whether GA reduces Aβ load in the treated mouse brains, mouse brain tissue sections were stained with thioflavin S (ThS) which selectively labels Aβ plaques (Fig 4A) .
First, APP/PS1 mice showed a significantly increased presence of Aβ plaques in the CA1, DG and cerebral cortex regions (Fig 4A) . There were no Aβ plaques found in the CA3 region (not shown). After one month of GA oral administration to the 9-month-old APP/PS1 mice (APP/PS1+GA group), the number of plaques per mm 2 area in the hippocampal CA1 and DG regions remained unchanged compared to that of the GA-treated APP/PS1 mice (Fig 4B, C) , except the number of Aβ plaques in the cerebral cortex, which showed significant reduction in the GA treated APP/PS1 mice group (Fig 4D) . Interestingly, the average size of Aβ plaques was significantly reduced in APP/PS1+GA group compared with those of the APP/PS1 group in the CA1, DG and cerebral cortex regions (Fig 4E-G) . These findings suggest that GA potentially prevented the formation of Aβ aggregation and plaque formation.
Gallic acid decreases Aβ1-42 aggregation and Aβ1-42-induced neuronal death in vitro
To further investigate the possibility that GA can reduce Aβ aggregation, the following four in vitro experiments were performed. First, thioflavin T (ThT) fluorescence densitometry assay was used to quantify the formation of Aβ fibrils in the presence of GA. At the ratio of 1:2 (Aβ:GA) and to a lesser extend at 1:1 (Aβ:GA), GA significantly inhibited the formation of Aβ fibrils over time in solution (Fig 5A) . Second, dynamic light scattering (DLS) was used to determine the size distribution profile of Aβ particles in solution suspension. Adding GA to the aggregated Aβ1-42 fibrils (Fig 5B) for 2 h clearly reduced the Aβ1-42 fibril particle size from predominantly 100 nm fibrils (blue colored bars) to about 60 nm sized particles (red colored bars). Third, the atomic force microscopy (AFM) technique was used to show that adding GA to the aggregated Aβ1-42 fibrils (Fig 5C) or co-incubating with Aβ1-42 clearly reduced the Aβ1-42 fibril particle size distribution profile. Fourth, indeed, the neurotoxicity of oligomeric Aβ1-42 mixtures, but not the fibrillar Aβ1-42, was significantly reduced in in vitro cultured cortical neurons by GA (Fig 5D) . Neuronal death of different kinds of Aβ1-42 mixtures were shown on each corresponding AFM pictures in Fig 5C and the corresponding viability shown in Fig 5D. Additionally, cultured cortical neurons preincubated with GA for 15 min before the addition of oligomeric forms Aβ1-42 also significantly protected against Aβ1-42 toxicity (Fig 5E) . At this condition, Aβ1-42 at 2.5 µM concentration killed 50% of cultured cortical neurons over 24 h period (Fig 5E) . In contrast, GA at 1 and 5 µM concentrations provided significant neuroprotection (p < 0.001). Glutamate-induced neurotoxicity and MK801 protection against glutamate toxicity were used as internal controls (Fig 5E) .
Taken together, these data clearly demonstrated that GA can effectively reduce Aβ1-42 fibril aggregation formation and neurotoxicity, which serves to explain the mechanism of GA's effect in neuroprotection. 
Oligomeric Aβ1-42 dose-dependently increases [(Ca 2+ )i] in cultured cortical neurons
GA attenuated oligomeric Aβ1-42-induced [Ca 2+ ]i in cultured cortical neurons and reduced neurotoxicity
To determine whether GA inhibits oligomeric Aβ-induced [(Ca 2+ )i] influx to neurons, cultured cortical neurons were treated with 2.5 µM oligomeric Aβ1-42 pre-mixed with GA (Fig 6D,E) .
Aβ1-42 used in this study was pre-polymerized and toxic to neurons as described in the Method section. From Fig 6D, (Fig 6F) , further supports the argument that the point of action for GA was not at the calcium channel level.
Molecular Modelling and Simulations of GA interaction with Aβ1-42
Non-covalent interactions: In order to provide a structural insight of GA disruption of Aβ1-42 aggregation, GA chemical derivatives were made which included 3-hydroxybenzoic acid, pyrogallol, 3,4-dihydroxybenzoic acid, 3,5-dihydroxybenzoic acid, and benzoic acid ( Fig   7A) . ThT fluorescence assay was used to determine whether these derivatives disrupt Aβ1-42 aggregation. As shown in Fig 7B and C, GA and pyrogallol significantly reduced Aβ aggregation-induced ThT fluorescence. In contrast, the rest of the GA derivatives was less effective (Fig 7C) , suggesting that the three hydroxyl groups were essential in reducing Aβ1-42 aggregation.
The crystal structure of fibrillar Aβ1-42 (PDB: 2MXU) is a S-shaped triple-β-motif, which is stabilized by a salt bridge between Lys28 and Ala42 residues. Docking studies revealed that the carboxylic acid group of GA forms hydrogen bond interactions with Lys28 and Ala42 residues, and these interactions were stabilized by hydrogen bonding with Val40 and hydrophobic interactions with Ile41 and Val39 residues (Fig 7D) . The hydrogen bonding interactions between GA and Lys28 and Ala42 residues might break the salt bridge between Lys28 and Ala42, resulting in instability of fibrillar Aβ1-42, and ultimately lead to disaggregation of Aβ1-42 fibrils.
Although hydrogen bonding interactions were observed between benzoic acid and residues Lys28 and Ala42, no additional hydrogen bonding interaction was formed with other residues. Thus, interaction between benzoic acid and Lys28 and Ala42 may be not potent enough to break the salt bridge (Fig 7F) . This suggests that the three hydroxyl groups play a role in stabilizing GA interaction with Aβ aggregation while the presence of the -COOH group is critical in destabilizing the Aβ1-42 fibrils.
Pyrogallol has additional binding sites on fibrillar Aβ1-42. Hydrogen bonding interactions were observed between pyrogallol and Asn27 and Ala30 residues (Fig 7E) . In addition, Van der Waal interactions with Phe19, Phe20, Ile31 and Ile41 residues were also observed ( Fig   7E) . Indeed, the crystal structure of fibrillar Aβ1-42 revealed that the inter-chain hydrogen bonding between residue Asn27 is important for the aggregation and fibrils formation.
Therefore, the stable hydrogen bonding interaction between pyrogallol and residue Asn27 may explain the disaggregation effect of pyrogallol on fibrillar Aβ1-42.
Covalent interactions:
Another possible disaggregation mechanism of GA derivatives may be through covalent modification. As shown in Fig 7G, GA and pyrogallol contain a catechol moiety which is easily oxidized to quinone and is susceptible to form covalent interaction with one or more lysine residues on Aβ1-42 via Schiff-base formation. This covalent interaction will disaggregate the fibrillar Aβ1-42. To demonstrate this interaction, a 20 covalent docking of GA quinone and pyrogallol quinone in monomers with Aβ1-42 was performed. As shown in Fig 7H and Fig 7I, both the oxidized product of GA and pyrogallol covalently interacted with Aβ1-42 through Schiff-base formation between the carbonyl group of the oxidized product and ε-amino group of Lys16. The van der Waals interactions between phenyl group of oxidized products and residues Phe20 and Phe19 contributed to the covalent modification. In addition, GA quinone forms an electrostatic interaction with His13. This may explain the lower activity of 3,4-dihydroxybenzoic acid than that of GA, as there is no hydroxyl group in the oxidized product of 3,4-dihydroxybenzoic acid, which means no hydrogen bonding interaction with His13 can be formed. These docking results also revealed that the oxidized product of GA and pyrogallol may be susceptible to form covalent interactions with Lys16, but not the Lys28 residue. We assumed that this may be due to the van der Waals interactions and electrostatic interaction with residues that are adjacent to Lys16. stage AD mice (9-month-old). These studies indicated to us that GA can potentially both prevent and treat AD. Our data showed that the neuroprotective functions of GA were mostly through its ability to reduce Aβ1-42 aggregation from forming toxic oligomers and fibrils based on evidence from the ThT assay, AFM, DLS and GA derivative interaction modeling studies.
DISCUSSION
Indeed, mixing GA with Aβ1-42 fibrils reduced Aβ1-42-induced calcium influx and protected cultured cortical neurons from toxicity.
The APP/PS1 transgenic mouse is an excellent model system to determine the development of cognitive impairments in mice over time. The 4-month-old APP/PS1 mice had very small amount of A plaque deposition in the brain and mild cognitive deficits in the spatial reference and working memories which resemble those seen during the early stage of AD development in humans. In contrast, the 9-month-old APP/PS1 transgenic mice showed a large amount of Aβ1-42 plaques in the brain and severely compromised cognitive functions.
This stage of disease development represents the late stage of AD seen in humans. GA treatment benefited both the early and late stage of APP/PS1 mice. The fact that GA significantly enhanced cognitive decline in APP/PS1 mice strongly suggests that GA is selective against Aβ1-42 and promises to serve as an effective drug candidate to delay and treat AD progression in humans.
Hippocampal LTP is considered one of the major cellular mechanisms underlying learning and memory. The 10-month-old APP/PS1 mice exhibited a significantly reduced LTP compared to those from the WT littermates and GA-treated mice (Fig 3) . This difference demonstrated a strong correlation of GA in enhancing synaptic strength of the APP/PS1 mouse brain, and which also led us to further investigate the possible mechanisms. Two possible mechanisms were investigated which included: (1) GA disrupting Aβ1-42 aggregation in vitro and in vivo; and (2) GA inhibiting intracellular calcium influx to neurons. Multiple lines of evidence from the present study showed that GA inhibits Aβ1-42 forming aggregates both in a test tube and in the brain of APP/PS1 mouse brain. Oral administration of GA to the APP/PS1 AD mice effectively reduced the Aβ1-42 plaque size, rather than the Aβ1-42 plaque number, adding weight to the suggestion that GA alters Aβ1-42 aggregation to reduce its toxicity.
This explains how GA treatment effectively reduced toxic Aβ1-42 load leading to long-term protection to synaptic functions.
Indeed, previous studies showed that GA was one of the most potent compounds in inhibiting kappa-casein fibril formation and stabilizing kappa-casein to prevent its aggregation 21 . GA can also inhibit α-synuclein aggregation, which is another critical factor in the pathogenesis of AD 38 . Based on the present atomic scale modeling studies and the ThT assay results, it is clear that the three hydroxyl groups of GA are essential in stabilizing the interaction of GA with Aβ1-42 aggregation. The -COOH group of GA appears to be essential in inhibiting the Aβ1-42 fibril formation. GA potentially disrupts the salt bridge between the residues of Lys28-Ala42 through non-covalent chemical bonding. Alternatively, oxidized GA and pyrogallol covalently interact with Aβ1-42 through Schiff-base formation between carbonyl group of the oxidized product and the ε-amino group of Lys16. Both interactions potentially alter the lateral association of layers of Aβ1-42 and prevent further Aβ1-42 aggregation.
NMDA receptor-mediated calcium influx is one of the major mechanisms of neuronal toxicity. Uncompetitive blockers of NMDA receptor-mediated intracellular calcium influx, such as memantine, confer potent protection against AD 18, 19 . Our data showed that GA could not completely inhibit glutamate and Aβ1-42 elicited intracellular calcium influx, indicating 23 that GA's protective effect was not through antagonizing these calcium receptors.
Interestingly, pre-mixing GA with aggregated Aβ1-42 effectively reduced calcium influx confirming that GA works at the level of inhibiting A aggregation.
There is ample circumstantial evidence to show that polyphenolic compounds from fruits, 
